granisetron has been researched along with Esophageal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T | 1 |
| Higuchi, K; Koizumi, W; Nagaba, S; Nakayama, N; Nonaka, M; Saigenji, K; Tanabe, S; Yago, K | 1 |
2 trial(s) available for granisetron and Esophageal Neoplasms
| Article | Year |
|---|---|
Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cross-Over Studies; Dexamethasone; Esophageal Neoplasms; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Stomach Neoplasms; Vomiting | 2016 |
A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzimidazoles; Cisplatin; Cross-Over Studies; Double-Blind Method; Endpoint Determination; Esophageal Neoplasms; Female; Granisetron; Humans; Male; Middle Aged; Patient Satisfaction; Vomiting | 2003 |